The GM-CSF–IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses

Author:

Arnold Isabelle C.12ORCID,Artola-Boran Mariela1,Gurtner Alessandra1,Bertram Katrin1,Bauer Michael1ORCID,Frangez Ziva3ORCID,Becher Burkhard2ORCID,Kopf Manfred4ORCID,Yousefi Shida3ORCID,Simon Hans-Uwe35ORCID,Tzankov Alexandar6ORCID,Müller Anne1

Affiliation:

1. Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland

2. Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

3. Institute of Pharmacology, University of Bern, Bern, Switzerland

4. Department of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland

5. Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia

6. Institute of Pathology, University Hospital of Basel, Basel, Switzerland

Abstract

The depletion of eosinophils represents an efficient strategy to alleviate allergic asthma, but the consequences of prolonged eosinophil deficiency for human health remain poorly understood. We show here that the ablation of eosinophils severely compromises antitumor immunity in syngeneic and genetic models of colorectal cancer (CRC), which can be attributed to defective Th1 and CD8+ T cell responses. The specific loss of GM-CSF signaling or IRF5 expression in the eosinophil compartment phenocopies the loss of the entire lineage. GM-CSF activates IRF5 in vitro and in vivo and can be administered recombinantly to improve tumor immunity. IL-10 counterregulates IRF5 activation by GM-CSF. CRC patients whose tumors are infiltrated by large numbers of eosinophils also exhibit robust CD8 T cell infiltrates and have a better prognosis than patients with eosinophillow tumors. The combined results demonstrate a critical role of eosinophils in tumor control in CRC and introduce the GM-CSF–IRF5 axis as a critical driver of the antitumor activities of this versatile cell type.

Funder

Swiss National Science Foundation

Publisher

Rockefeller University Press

Subject

Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3